EMA Authorised: Zessly (infliximab) — Sandoz GmbH

View source ↗

Summary

EMA authorised Zessly (infliximab) from Sandoz GmbH as a biosimilar for treatment of several inflammatory diseases, including rheumatoid arthritis, psoriatic ar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Zessly (infliximab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Psoriasis;Crohn Disease;Arthritis, Rheumatoid;Colitis, Ulcerative;Spondylitis, Ankylosing. MAH: Sandoz GmbH. Decision date: 19/06/2025